SAB Biotherapeutics Announces Publication of Nonclinical Data Demonstrating SAB-185 Has High Potency…
In the FDA-conducted study, SAB-185 consistently demonstrated high avidity and high potency for effectively neutralizing a broad range of SARS-CoV-2 strains and variants through Delta SAB-185 additionally outperformed convalescent plasma…